To investigate bronchopulmonary dysplasia (BPD) and its treatment with dexamethasone (DEX) in premature infants with birth weight (BW) < 1500 g. We retrospectively reviewed the records of preterm infants admitted to the Division of Neonatology, the Second Xiangya Hospital, Central South University between September 2011 and December 2014. Patients were excluded if they needed oxygen therapy but were lost to follow-up at ≤36 weeks post-menstrual age (PMA) or <56 days after birth, or they had severe congenital anomalies. The incidence of BPD was 18% (37/212). Gestational age (GA) was <32 weeks in all BPD patients. GA, BW, and Apgar scores were lower and hospitalization duration and pulmonary surfactant (PS) use were higher in the BPD group than in the non-BPD group (P < 0.05). Risk factors for BPD included neonatal respiratory distress syndrome, neonatal pneumonia, positive sputum culture, pulmonary hemorrhage, respiratory failure. Multivariate logistic regression revealed that GA (odds ratio [OR]: 0.479, P = 0.004) and neonatal respiratory distress syndrome (OR: 6.146, P = 0.043) were independent risk factors for BPD. DEX was administered to 26 patients after the diagnosis of BPD. After one and two weeks of DEX treatment, the oxygen requirement had significantly reduced compared to the week prior to treatment (P < 0.05), while during treatment, the weight gain rate and weight gain efficiency slower significantly than that during either of the two preceding weeks (P < 0.001). These results suggest that low GA was the most important risk factor for BPD, DEX reduced oxygen dependency but decreased weight gain.
Introduction
With improvements in neonatal emergency care, preterm infants, particularly very low birth weight (VLBW) infants (<1500 g), now have significantly increased survival rates. According to the foreign studies, Bronchopulmonary dysplasia (BPD) remains a major threat because it adversely affects the prognosis of VLBW infants; similar work in domestic of this issue is relatively less. Furthermore, specific treatment methods are lacking, and research into the prevention and amelioration of BPD is urgently required [1] .
This retrospective study assessed the prevalence of BPD in VLBW infants over the last 3 years, analyzed the risk factors and clinical features associated with BPD, and determined the short-term efficacy and safety of dexamethasone (DEX) treatment. The aim of this study was to summary clinical evidence for an optimal prevention and treatment therapy of BPD.
Patients and Methods

Diagnostic Criteria for BPD
The diagnosis of BPD is based on the need for supplemental oxygen for at least 28 days after birth, and its severity is graded according to the respiratory support required at 36 weeks post-menstrual age (PMA) (GA < 32 weeks) or at 56 days after birth (GA ≥ 32 weeks) as follows: 1) mild, breathing room air; 2) moderate, FiO 2 < 0.3; and 3) severe, FiO 2 ≥ 0.3 with mechanical ventilation if required [2] .
Study Protocol
We collected the clinical data of premature infants who had a birth weight of <1500 g and were treated in the neonatal intensive care unit at our hospital between September 1 st , 2011, and December 31 st , 2014. The inclusion criteria were a hospital stay beyond 36
weeks PMA (GA > 32 weeks) or 56 days after birth (GA ≥ 32 weeks), or discharge with no need for additional oxygen within this period. Patients were excluded if they still required oxygen therapy but were discharged before 36 weeks PMA (GA < 32 weeks) or 56 days after birth (GA ≥ 32 weeks). Patients with severe congenital anomalies or with missing clinical information (i.e., degree of prematurity, type of oxygen therapy) were also excluded. The patients were categorized into a BPD group and a non-BPD group, according to the diagnostic criteria mentioned above. This study protocol was approved by the ethics committee of Central South University.
Statistical Analysis
The results are expressed as means with SD or medians with interquartile for conti-nuous data and frequencies for discrete data, data were analyzed using t-tests, Chi- were considered statistically significant.
Results
General Characteristics
Between September 1 st , 2011 and December31 st , 2014, 273 premature infants with a birth weight of <1500 g were treated at our hospital, of whom 212 infants met the inclusion criteria for our study; 114 were boys, and 98 were girls. Their median GA was 30 +4 weeks (interquartile range: 29 +1 to 32weeks), and their median birth weight was 1315 g (interquartile range: 1160 to 1407 g). Thirty-seven patients met the diagnostic criteria for BPD, giving an incidence of 18% (37/212). The BPD incidence in infants with a birth weight of <1000 g was 37% (6/16), while the incidence in infants with a birth weight of 1000-1499 g was 16% (31/196 ).
All cases of BPD occurred in infants born at a GA of <32 weeks, in which the incidence of BPD was 23% (37/160). The incidence of BPD was 56% (9/16) in infants born at a GA of ≤28 weeks, 31% in infants born between 28 +1 and 30 weeks (22/72), and only 8% in infants born at over 30 +1 (6/72). Table 1 reveals the differences between BPD and non-BPD group. GA, birth weight, and 1and 5-min Apgar scores were significantly lower and the duration of hospitalization was significantly higher in the BPD group than in the non-BPD group (P < 0.05 for all). In addition, the rates of neonatal respiratory distress syndrome (NRDS), neonatal pneumonia, positive sputum culture, pulmonary hemorrhage, apnea, respiratory failure, sepsis, blood-stained amniotic fluid, and use of pulmonary surfactant (PS) were higher in the BPD group (P < 0.05 for all). The mothers of children in the BPD group were less likely to have had pregnancy-induced hypertension and delivered small for gestational age (SGA) infants than the mothers of children in the non-BPD group (P < Table 2 ).
Clinical Characteristics and Risk Factors Associated with BPD
The cumulative duration of oxygen therapy and mechanical ventilation within each of 7, 14, 21, 28 days after birth were significantly greater in the BPD group than in the non-BPD group (P < 0.001; Figure 1 and Figure 2 ).
Treatment of BPD with DEX
Adequate information was provided to the guardian of each patient regarding to DEX benefits and risks, informed consent was obtained then, 26 infants diagnosed with BPD With regards to weight gain, as shown in Figure 4 , there was no difference in the weight gain rates in the 2 weeks preceding the administration of DEX (13.5 ± 5.0 g/kg/d vs. 15.8 ± 7.6 g/kg/d for 1 and 2 weeks prior to DEX treatment, respectively; P = 0.203).
After the first week of DEX treatment, the rate of weight gain slowed significantly compared to both 1 and 2 weeks before the intervention (6.3 ± 6.6 g/kg/d; P < 0.001). As show in Figure 4 , an analysis of the changes in weight gain before and after the use of DEX showed that the weight gain per unit of energy intake in the week before the initiation of DEX therapy (0.11 ± 0.05 g/kcal) did not significantly differ from that 2 weeks before treatment was started (0.13 ± 0.06 g/kcal; P = 0.205). During DEX treatment, the weight gain per unit of energy intake was significantly lower (0.05 ± 0.05 g/kcal) than that during either of the two preceding weeks (P < 0.001).
The following complications occurred in the 26 BPD patients who were treated with DEX: feeding intolerance (n = 3, including one case of abdominal distension), increased white blood cell count (n = 5), electrolyte imbalance (n = 3; hyponatremia, n = 1; hyperkalemia, n = 1; and hypocalcemia, n = 1), hyperglycemia (n = 2) and localized edema (n = 3; limb edema, n = 1; edema of both lower limbs and the lumbosacral region, n = 1; edema of the lower limbs and perineal edema, n = 1). There were no cases of upper gastrointestinal bleeding/perforation, infection or hypertension.
Discussion
Since [7] . A study from India reported that the incidence of BPD was as high as 52.8% [8] . These high incidence rates suggest that BPD is a major complication in VLBW infants worldwide and can seriously affect the prognosis of premature children.
In the early days of research into BPD, high concentrations of oxygen and positive pressure ventilation were determined to be the major causes. BPD was equivalent to "oxygen toxicity," a serious complication of NRDS, with pathological findings of obstructive bronchitis and pulmonary fibrosis [9] . After exogenous PS became widely used clinically, the incidence of this "classical BPD" gradually reduced. Instead, "new BPD" has increased clinical focus. The dominant pathological finding in "new BPD"
isan arrest in alveolar development, resulting in lungs with large and simplified airspaces with relatively infrequent fibrosis [10] . Currently, most researchers agree with the hypothesis that BPD is a developmental disorder that results from interference with the process of pulmonary maturation, leading to developmental maturation abnormalities of the structures and functions of the distal lung parenchyma [11] [12] [13] . Thus, lung injuries in BPD are attributable to hyperoxia, barotrauma, stress and pulmonary immaturity, as well as infections, intrauterine hypoxia and patent ductus arteriosus [14] [15] [16] [17] [18] .
This study demonstrated that BPD occurred in premature infants born at a GA of ≤32 weeks; GA was significantly lower in the BPD group than in the non-BPD group.
Furthermore, the lower was the GA, the higher the incidence of BPD. The incidence of BPD in infants with a GA of ≤28 weeks was 56%. Logistic regression analysis showed that GA was an independent risk factor for the occurrence of BPD. Thus, the factor that was most closely related to the development of BPD in our study population was con-sistent with the generally accepted view [19] [20] . The consequences of BPD on infants born at early GA stages emphasizes that this outcome should be considered in all patients with a low GA, and stronger precautions against preterm birth are vital.
In the current study, patients in the BPD group had a higher probability of developing NRDS, neonatal pneumonia, pulmonary hemorrhage and other respiratory diseases, as well as having a positive sputum culture, than patients in the non-BPD group.
Logistic regression analysis showed that NRDS was an independent risk factor for BPD, which suggests that the incidence of BPD in premature lungs depends on a variety of factors that lead to lung injury.
Patients in the BPD group were more likely to have received PS than patients in the non-BPD group. This finding was not in accordance with previous studies that have shown that PS protects against BPD [21] [22] . In the present study, the higher rate of PS use in the BPD group was related to the lower GA and higher incidence of NRDS in this group. These factors necessitated the use of PS for the prevention and treatment of NRDS. Thus, it would be erroneous to conclude that PS use increased the incidence of BPD.
Increasing evidence has been published that suggests an adverse intrauterine environment damages lung development, especially alveolar development, and leads to persistent changes in lung structure and postnatal respiratory compromise; thereby, SGA premature infants have been reported to have an increased incidence of BPD [23] [24] .
As the respiratory dysfunction persists during postnatal development, the incidence of respiratory-related illnesses and mortality in adulthood is also significantly increased in SGA infants [25] . Even children with an appropriate for gestational age (AGA) weight have a significantly higher probability of BPD if their birth weight is less than the average weight for their GA [26] . Although the relationship between SGA weight and late pulmonary function abnormalities is unknown, evidence from animal models has indicated that intrauterine growth retardation factors, including malnutrition and hypoxia, can affect fetal lung development, impair the development of the terminal alveoli, inhibit the synthesis of PS, reduce the expression of surfactant, and induce inflammatory injury, thus increasing the risk of BPD [27] [28] [29] [30] . However, in our study, the rates of maternal pregnancy-induced hypertension and SGA infants were significantly lower in the BPD group than in the non-BPD group. In this view, although chronic intrauterine hypoxia and other adverse factors may directly affect fetal lung development, SGA children still will be more likely to have a more mature lung than AGA infants while with a similar birth weight, and lower GA may have a greater impact on lung development than other potentially injurious factors, such as intrauterine growth retardation, further prospective studies with larger sample sizes are needed to investigate whether it is true.
Oxygen toxicity as a result of high oxygen concentrations and pressure injuries due to positive pressure ventilation are considered to be important factors in the pathogenesis of BPD. This current study showed significant differences between the BPD and the non-BPD group with regards to the cumulative duration of oxygen therapy and mechanical ventilation in the first 4 postnatal weeks. These findings suggest that oxygen-related lung injury is an important risk factor for BPD, the requirement for supplemental oxygen or mechanical ventilation, as one of its main clinical features, increased the duration and the expense of hospitalization indirectly. DEX, a long-acting glucocorticoid, has been used in clinic for it could significantly shorten the duration of mechanical ventilation and reduce the incidence of BPD and death [31] [32]. However, the potential adverse outcome in neurodevelopment make the clinician more prudently. In this study, our clinicians would discuss the potential benefits, risks and relevant solutions of DEX with each guardian of BPD infants. 26 BPD infants received DEX treatment as a therapeutic intervention since their parent signed a written agreement.
A comparison of the data obtained before and after DEX treatment revealed that the duration of oxygen therapy and mechanical ventilation were significantly reduced in infants diagnosed with BPD, effectively reducing their oxygen dependency. However, these current results do not enable conclusions to be made regarding whether DEX can alleviate BPD severity or improve long-term pulmonary outcomes, such as lung function. Future case-control studies will be required to confirm these findings.
Hypertension, gastrointestinal perforation and other serious adverse short-term complications did not occur after DEX treatment in our patients. However, weight gain rate was significantly lower after DEX treatment than before this treatment, and the weight gain per unit energy intake, which was calculated to indicate the amount of body weight gained per kilojoule of energy consumed, reflecting feed efficiency, was significantly declined as well. As we know, The adrenocorticoid receptor(ACR) is an important nuclear transcription factor. In the absence of glucocorticoids, ACR binds to heat shock proteins (HSPs) in the cytoplasm, such as HSP-90, HSP-70 and FKBP52, whichare rapidly translocated into the nucleus by importin molecules. In the nucleus, they bind to hormone response units, regulate target gene expression and participate in essential cellular processes, including energy metabolism, protein synthesis and signal transduction [33] . Thus, we suppose that the increased energy metabolismin the body caused by DEX, such as inhibition on anabolism and enhancement on catabolism of protein, may be the main cause for the deceased weight gain rate and feed efficiency.
Further analysis of the intrinsic mechanism was also required. Anyway, for effective weight gain during DEX treatment, the supply of nutrients must be sufficient, evenaugmented to some extent.
Conclusion
BPD is a common complication in premature children with a birth weight of <1500 g, and GA is an important predictor of BPD. The use of DEX can significantly shorten the duration of oxygen therapy in children with BPD, but may reduce weight gain.
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